SUNNYVALE, CA--(Marketwire - June 14, 2011) -
Highlighted Links |
http://www.protrials.com |
Significant company milestones include:
- the completion of a large, 600-site cardiovascular study involving 5,500 patients
- the expansion of its range of expertise in ophthalmology studies, including the completion of a study involved in a successful BLA (Biologic License Application) submission and several studies resulting in FDA approval of a major ophthalmology compound
- staffing increase to 100 professionals averaging 15+ years of clinical trial experience
"Throughout our growth spurt, we've continued to focus on our core values: service, quality and experience," said Jodi Andrews, CEO of ProTrials. "As a result, we now offer our increasing roster of sponsors significant expertise in many therapeutic areas, particularly cardiovascular, oncology, immunology and ophthalmology. Going forward, we will continue to expand on this, as well as our international service range and staffing."
ProTrials regularly participates in industry-wide educational events. Visitors to the 47th Annual Meeting of the Drug Information Association (DIA 2011), being held June 19-23 McCormick Place in Chicago, can learn more about the company in Booth 901.
About ProTrials Research, Inc.
Founded in 1996, ProTrials Research, Inc. is a specialized contract research organization (CRO) with regional clinical research associates and project managers based throughout North America, Canada, and Europe. The company works with clients in the pharmaceutical, biotechnology and medical device industries, providing cost-effective site monitoring, project management and associated clinical operations services. ProTrials is headquartered in Sunnyvale, California. For more information, visit www.protrials.com or call (650) 864-9180.